ゲノム編集市場の市場規模、シェア、動向分析レポート：技術別、送達方法別、用途別、モード別、最終用途別、地域別、セグメント予測、2025年～2030年

ゲノム編集市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のゲノム編集市場規模は2030年に250億米ドルに達し、2025～2030年にかけて16.1％のCAGRで成長すると予測されています。

ゲノム編集技術の進歩の増加、ゲノミクス産業への資金調達と投資の増加、遺伝性疾患の有病率の増加、治療と療法の改善の必要性は、収益成長を促進する主要因です。

ゲノム編集技術の進化は、市場の収益成長を促進するもう1つの要因です。CRISPR-Cas13、プライム編集、塩基編集などを含む新しく先進的ゲノム編集法の強化により、最も効果的で正確な遺伝子編集が可能になりました。これにより、学術的・医療的な文脈でより頻繁に使用されるゲノム編集法が生まれます。例えば、2020年1月、ERS GenomicsとNew England BiolabはCRISPR遺伝子改変ツール＆試薬の開発と商業化のために協力しました。

遺伝子改変ツールの治療研究への応用が進むにつれて、臨床検査に入る先端治療の数が増加しています。さらに、新しい遺伝子改変システムの実装を進めるための人工知能の使用は、技術開発者にとって大きな可能性を示しています。このことは、予測可能な将来において、収益獲得に大きく有利に働くと予想されます。研究コミュニティは、CRISPRのような遺伝子改変装置が、様々な慢性疾患の迅速なスクリーニングソリューションとなりうる可能性を探っています。このような研究プログラムは、今後数年間、ゲノム編集市場に利益をもたらす可能性が高いです。

ゲノム編集市場レポートハイライト

• 遺伝子編集技術CRISPRは、バイオテクノロジーにおける急成長技術になると予測されます。CRISPRは細菌の免疫系を利用して遺伝子をノックアウトするか、新しい遺伝子を挿入します。
• ゲノム編集技術の急速な進歩は、治療の展望を再構築し、広範な遺伝性疾患、血液疾患、代謝性疾患、感染性疾患の治療を目的とした臨床検査の急増を促しています。
• In vivoゲノム編集は、世界の治療状況を一変させる力として台頭しつつあります。従来型ex vivoの方法とは異なり、in vivoのアプローチでは患者の体内で直接遺伝子を改変することができるため、複雑な細胞の抽出、操作、再灌流が不要になります。
• CRISPR/Cas9セグメントは、2024年の世界売上高で44.36%の最大市場シェアを占めました。これは、高い精度と効率性、高い汎用性と異なる実験デザインへの適応性、関連費用が比較的低い費用対効果に起因します。
• 北米のゲノム編集市場は、遺伝子編集技術の研究開発への投資が増加していることから、世界市場を独占し、2024年には44.59％のシェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ゲノム編集市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/補助的な市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ゲノム編集市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 ゲノム編集市場：技術別、推定・動向分析

• セグメントダッシュボード
• 世界のゲノム編集市場の技術変動分析
• 世界のゲノム編集市場規模と動向分析（技術別、2018～2030年）
• （クリスパー）/Cas9
• TALEN/メガTAL
• ZFN
• メガヌクレアーゼ
• その他

第5章 ゲノム編集市場：送達方法推定・動向分析

• セグメントダッシュボード
• 世界のゲノム編集市場の送達方法変動分析
• 世界のゲノム編集市場規模と動向分析（送達方法別、2018～2030年）
• 生体外
• 生体内

第6章 ゲノム編集市場：用途推定・動向分析

• セグメントダッシュボード
• 世界のゲノム編集市場の用途変動分析
• 世界のゲノム編集市場規模と動向分析（用途別、2018～2030年）
• 遺伝子工学
  • 細胞株工学
  • 動物遺伝子工学
  • 植物遺伝子工学
  • その他
• 臨床用途
  • 診断開発
  • 治療法の開発

第7章 ゲノム編集市場：モード推定・動向分析

• セグメントダッシュボード
• 世界のゲノム編集市場のモード変動分析
• 世界のゲノム編集市場規模と動向分析（モード別、2018～2030年）
• 契約
• 社内

第8章 ゲノム編集市場：最終用途推定・動向分析

• セグメントダッシュボード
• 世界のゲノム編集市場の最終用途変動分析
• 世界のゲノム編集市場規模と動向分析（最終用途別、2018～2030年）
• バイオテクノロジーと製薬会社
• 学術機関と政府研究機関
• 契約研究機関

第9章 ゲノム編集市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 競合情勢

• 企業/競合の分類
• 戦略マッピング
• 企業市況分析、2024年
• 企業プロファイル/上場企業
  • Merck KGaA
  • Takara Bio Inc.
  • Revvity, Inc.
  • Danaher Corporation
  • GenScript
  • New England Biolabs
  • Charles River Laboratories
  • Eurofins Scientific
  • Lonza
  • Thermo Fisher Scientific, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 Global genome editing market, by region, 2018 - 2030 (USD Million)
• Table 3 Global genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 4 Global genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 5 Global genome editing market, by application, 2018 - 2030 (USD Million)
• Table 6 Global genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 7 Global genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 8 Global genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 9 Global genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 10 North America genome editing market, by country, 2018 - 2030 (USD Million)
• Table 11 North America genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 12 North America genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 13 North America genome editing market, by application, 2018 - 2030 (USD Million)
• Table 14 North America genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 15 North America genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 16 North America genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 17 North America genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 18 U.S. genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 19 U.S. genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 20 U.S. genome editing market, by application, 2018 - 2030 (USD Million)
• Table 21 U.S. genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 22 U.S. genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 23 U.S. genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 24 U.S. genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 25 Canada genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 26 Canada genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 27 Canada genome editing market, by application, 2018 - 2030 (USD Million)
• Table 28 Canada genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 29 Canada genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 30 Canada genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 31 Canada genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 32 Mexico genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 33 Mexico genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 34 Mexico genome editing market, by application, 2018 - 2030 (USD Million)
• Table 35 Mexico genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 36 Mexico genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 37 Mexico genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 38 Mexico genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 39 Europe genome editing market, by country, 2018 - 2030 (USD Million)
• Table 40 Europe genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 41 Europe genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 42 Europe genome editing market, by application, 2018 - 2030 (USD Million)
• Table 43 Europe genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 44 Europe genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 45 Europe genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 46 Europe genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 47 Germany genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 48 Germany genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 49 Germany genome editing market, by application, 2018 - 2030 (USD Million)
• Table 50 Germany genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 51 Germany genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 52 Germany genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 53 Germany genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 54 UK genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 55 UK genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 56 UK genome editing market, by application, 2018 - 2030 (USD Million)
• Table 57 UK genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 58 UK genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 59 UK genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 60 UK genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 61 France genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 62 France genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 63 France genome editing market, by application, 2018 - 2030 (USD Million)
• Table 64 France genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 65 France genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 66 France genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 67 France genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 68 Italy genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 69 Italy genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 70 Italy genome editing market, by application, 2018 - 2030 (USD Million)
• Table 71 Italy genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 72 Italy genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 73 Italy genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 74 Italy genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 75 Spain genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 76 Spain genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 77 Spain genome editing market, by application, 2018 - 2030 (USD Million)
• Table 78 Spain genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 79 Spain genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 80 Spain genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 81 Spain genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 82 Denmark genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 83 Denmark genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 84 Denmark genome editing market, by application, 2018 - 2030 (USD Million)
• Table 85 Denmark genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 86 Denmark genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 87 Denmark genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 88 Denmark genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 89 Sweden genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 90 Sweden genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 91 Sweden genome editing market, by application, 2018 - 2030 (USD Million)
• Table 92 Sweden genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 93 Sweden genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 94 Sweden genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 95 Sweden genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 96 Norway genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 97 Norway genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 98 Norway genome editing market, by application, 2018 - 2030 (USD Million)
• Table 99 Norway genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 100 Norway genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 101 Norway genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 102 Norway genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 103 Asia Pacific genome editing market, by country, 2018 - 2030 (USD Million)
• Table 104 Asia Pacific genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 105 Asia Pacific genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 106 Asia Pacific genome editing market, by application, 2018 - 2030 (USD Million)
• Table 107 Asia Pacific genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 108 Asia Pacific genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 109 Asia Pacific genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 110 Asia Pacific genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 111 China genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 112 China genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 113 China genome editing market, by application, 2018 - 2030 (USD Million)
• Table 114 China genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 115 China genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 116 China genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 117 China genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 118 Japan genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 119 Japan genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 120 Japan genome editing market, by application, 2018 - 2030 (USD Million)
• Table 121 Japan genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 122 Japan genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 123 Japan genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 124 Japan genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 125 India genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 126 India genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 127 India genome editing market, by application, 2018 - 2030 (USD Million)
• Table 128 India genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 129 India genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 130 India genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 131 India genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 132 South Korea genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 133 South Korea genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 134 South Korea genome editing market, by application, 2018 - 2030 (USD Million)
• Table 135 South Korea genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 136 South Korea genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 137 South Korea genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 138 South Korea genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 139 Australia genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 140 Australia genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 141 Australia genome editing market, by application, 2018 - 2030 (USD Million)
• Table 142 Australia genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 143 Australia genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 144 Australia genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 145 Australia genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 146 Thailand genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 147 Thailand genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 148 Thailand genome editing market, by application, 2018 - 2030 (USD Million)
• Table 149 Thailand genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 150 Thailand genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 151 Thailand genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 152 Thailand genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 153 Latin America genome editing market, by country, 2018 - 2030 (USD Million)
• Table 154 Latin America genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 155 Latin America genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 156 Latin America genome editing market, by application, 2018 - 2030 (USD Million)
• Table 157 Latin America genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 158 Latin America genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 159 Latin America genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 160 Latin America genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 161 Brazil genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 162 Brazil genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 163 Brazil genome editing market, by application, 2018 - 2030 (USD Million)
• Table 164 Brazil genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 165 Brazil genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 166 Brazil genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 167 Brazil genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 168 Argentina genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 169 Argentina genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 170 Argentina genome editing market, by application, 2018 - 2030 (USD Million)
• Table 171 Argentina genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 172 Argentina genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 173 Argentina genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 174 Argentina genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 175 MEA genome editing market, by country, 2018 - 2030 (USD Million)
• Table 176 MEA genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 177 MEA genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 178 MEA genome editing market, by application, 2018 - 2030 (USD Million)
• Table 179 MEA genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 180 MEA genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 181 MEA genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 182 MEA genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 183 South Africa genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 184 South Africa genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 185 South Africa genome editing market, by application, 2018 - 2030 (USD Million)
• Table 186 South Africa genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 187 South Africa genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 188 South Africa genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 189 South Africa genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 190 Saudi Arabia genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 191 Saudi Arabia genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 192 Saudi Arabia genome editing market, by application, 2018 - 2030 (USD Million)
• Table 193 Saudi Arabia genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 194 Saudi Arabia genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 195 Saudi Arabia genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 196 Saudi Arabia genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 197 UAE genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 198 UAE genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 199 UAE genome editing market, by application, 2018 - 2030 (USD Million)
• Table 200 UAE genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 201 UAE genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 202 UAE genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 203 UAE genome editing market, by end-use, 2018 - 2030 (USD Million)
• Table 204 Kuwait genome editing market, by technology, 2018 - 2030 (USD Million)
• Table 205 Kuwait genome editing market, by delivery method, 2018 - 2030 (USD Million)
• Table 206 Kuwait genome editing market, by application, 2018 - 2030 (USD Million)
• Table 207 Kuwait genome editing market, for genetic engineering, by application, 2018 - 2030 (USD Million)
• Table 208 Kuwait genome editing market, for clinical applications, by application, 2018 - 2030 (USD Million)
• Table 209 Kuwait genome editing market, by mode, 2018 - 2030 (USD Million)
• Table 210 Kuwait genome editing market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Genome editing market segmentation
• Fig. 2 Data analysis models
• Fig. 3 Market formulation and validation
• Fig. 4 Data validating & publishing
• Fig. 5 Market research process
• Fig. 6 Information procurement
• Fig. 7 Primary research
• Fig. 8 Value-chain-based sizing & forecasting
• Fig. 9 QFD modelling for market share assessment
• Fig. 10 Market formulation & validation
• Fig. 11 Commodity flow analysis
• Fig. 12 Market outlook
• Fig. 13 Segment snapshot-1
• Fig. 14 Segment snapshot-2
• Fig. 15 Segment snapshot-3
• Fig. 16 Competitive landscape snapshot
• Fig. 17 Life science tools market value, 2024 (USD Billion)
• Fig. 18 Market trends & outlook
• Fig. 19 PESTEL analysis
• Fig. 20 Porter's five forces analysis
• Fig. 21 Genome editing market: Technology outlook key takeaways
• Fig. 22 Genome editing market: Technology movement analysis
• Fig. 23 CRISPR/Cas9 market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 TALENs/MegaTALs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 ZFN market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Meganucleases market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Genome editing market: Delivery method outlook key takeaways
• Fig. 29 Genome editing market: Delivery method movement analysis
• Fig. 30 Ex vivo market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 In vivo market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Genome editing market: Application outlook key takeaways
• Fig. 33 Genome editing market: Application movement analysis
• Fig. 34 Genetic engineering market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Cell line engineering market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Animal genetic engineering market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Plant genetic engineering market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Clinical applications market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Diagnostics development market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Therapy development market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Genome editing market: Mode outlook key takeaways
• Fig. 43 Genome editing market: Mode movement analysis
• Fig. 44 Contract market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 In-house market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Genome editing market: End-use outlook key takeaways
• Fig. 47 Genome editing market: End-use movement analysis
• Fig. 48 Biotechnology and pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Academic and government research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Contract research organizations market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Regional marketplace outlook, 2024 & 2030 (USD Million)
• Fig. 52 Regional marketplace: Key takeaways
• Fig. 53 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Genome Editing Market Growth & Trends:

The global genome editing market size is expected to reach USD 25.00 billion in 2030 and is projected to grow at a CAGR of 16.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing advancements in genome editing technology, the growing funding & investments in the genomics industry, the increasing prevalence of genetic disorders, and the need for improved treatments and therapies are major factors driving revenue growth.

The evolution of genome editing technologies is another contributing factor to drive revenue growth in the market. Most effective and accurate gene editing is now possible through the enhancement of new and advanced genome editing methods including CRISPR-Cas13,prime editing, and base editing, amongst others. This creates genome editing methods used more often in academic and medical contexts. For instance, in January 2020, ERS Genomics and New England Biolab collaborated to develop and commercialize CRISPR gene modification tools & reagents.

The increasing application of gene-modification tools in therapeutic research has resulted in the rising number of advanced therapeutics entering clinical trials. Furthermore, the use of artificial intelligence to advance the implementation of novel gene modification systems exhibits great potential for the technology developer. This is anticipated to greatly favor revenue generation in the foreseeable future. Research communities are exploring the potential of gene-modification instruments such as CRISPR as a potential fast screening solution for various chronic diseases. Such research programs are likely to benefit the market for genome editing in the coming years.

Genome Editing Market Report Highlights:

• Gene editing technology CRISPR is projected to be the burgeoning technology in biotechnology. CRISPR harnesses the bacterial immune system to either knock genes out or insert new genes.
• The rapid advancement of genome editing technologies is reshaping the therapeutic landscape, driving a surge in clinical trials aimed at treating a wide range of genetic, hematologic, metabolic, and infectious diseases.
• In vivo genome editing is emerging as a transformative force within the global therapeutic landscape. Unlike traditional ex vivo methods, in vivo approaches allow for direct gene modification inside the patient's body, eliminating the need for complex cell extraction, manipulation, and reinfusion.
• The CRISPR/Cas9 segment held the largest market share of 44.36% of the global revenue in 2024. This can be attributed to high precision & efficiency, high versatility & adaptability to different experimental designs, and cost-effectiveness with relatively low expense associated
• North America genome editing market dominated the global market and accounted for a 44.59% share in 2024, owing to the growing investments in the R&D of gene editing technologies.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology Segment
  • 1.2.2. Delivery Method Segment
  • 1.2.3. Application Segment
  • 1.2.4. Mode Segment
  • 1.2.5. End-use Segment
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Genome Editing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Success in pre-clinical models drives demand for genome editing therapeutics
    • 3.2.1.2. Rising competition amongst market participants for business development
    • 3.2.1.3. Easy editing solutions for the development of therapeutics for a broad range of diseases
    • 3.2.1.4. Increasing demand for synthetic genes and genetically modified organisms
    • 3.2.1.5. Technological advancements in gene editing technologies
    • 3.2.1.6. Rising adoption in agricultural biotechnology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Challenges concerning clinical translation
    • 3.2.2.2. Regulatory, scientific, and ethical challenges regarding the use of genetically modified products
    • 3.2.2.3. Off-target effects of CRISPR technology
• 3.3. Genome Editing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Genome Editing Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Genome Editing Market Technology Movement Analysis
• 4.3. Global Genome Editing Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 4.4. (CRISPR)/Cas9
  • 4.4.1. (CRISPR)/Cas9 market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. TALENs/MegaTALs
  • 4.5.1. TALENs/MegaTALs market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. ZFN
  • 4.6.1. ZFN market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Meganuclease
  • 4.7.1. Meganuclease market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Genome Editing Market: Delivery Method Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Genome Editing Market Delivery Method Movement Analysis
• 5.3. Global Genome Editing Market Size & Trend Analysis, by Delivery Method, 2018 to 2030 (USD Million)
• 5.4. Ex Vivo
  • 5.4.1. Ex vivo market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. In-Vivo
  • 5.5.1. In-vivo market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Genome Editing Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Genome Editing Market Application Movement Analysis
• 6.3. Global Genome Editing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Genetic Engineering
  • 6.4.1. Genetic Engineering market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Cell Line Engineering
    • 6.4.2.1. Cell line engineering market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Animal Genetic Engineering
    • 6.4.3.1. Animal genetic engineering market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Plant Genetic Engineering
    • 6.4.4.1. Plant genetic engineering market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Others
    • 6.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Clinical Applications
  • 6.5.1. Clinical applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Diagnostics Development
    • 6.5.2.1. Diagnostics development market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Therapy Development
    • 6.5.3.1. Therapy development market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Genome Editing Market: Mode Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Genome Editing Market Mode Movement Analysis
• 7.3. Global Genome Editing Market Size & Trend Analysis, by Mode, 2018 to 2030 (USD Million)
• 7.4. Contract
  • 7.4.1. Contract market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. In-house
  • 7.5.1. In-house market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Genome Editing Market: End-Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Genome Editing Market End-Use Movement Analysis
• 8.3. Global Genome Editing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
• 8.4. Biotechnology and pharmaceutical companies
  • 8.4.1. Biotechnology and pharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Academic and government research institutes
  • 8.5.1. Academic and government research institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Contract research organizations
  • 8.6.1. Contract research organizations market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Genome Editing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.4. North America
  • 9.4.1. U.S.
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework
    • 9.4.1.3. Target disease prevalence
    • 9.4.1.4. Competitive scenario
    • 9.4.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.2. Canada
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Target disease prevalence
    • 9.4.2.4. Competitive scenario
    • 9.4.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.3. Mexico
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Target disease prevalence
    • 9.4.3.4. Competitive scenario
    • 9.4.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.5. Europe
  • 9.5.1. UK
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework
    • 9.5.1.3. Target disease prevalence
    • 9.5.1.4. Competitive scenario
    • 9.5.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. Germany
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Target disease prevalence
    • 9.5.2.4. Competitive scenario
    • 9.5.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. France
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Target disease prevalence
    • 9.5.3.4. Competitive scenario
    • 9.5.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Italy
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Target disease prevalence
    • 9.5.4.4. Competitive scenario
    • 9.5.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.5. Spain
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Target disease prevalence
    • 9.5.5.4. Competitive scenario
    • 9.5.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.6. Norway
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Target disease prevalence
    • 9.5.6.4. Competitive scenario
    • 9.5.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.7. Sweden
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Target disease prevalence
    • 9.5.7.3. Regulatory framework
    • 9.5.7.4. Competitive scenario
    • 9.5.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.8. Denmark
    • 9.5.8.1. Key country dynamics
    • 9.5.8.2. Regulatory framework
    • 9.5.8.3. Target disease prevalence
    • 9.5.8.4. Competitive scenario
    • 9.5.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Japan
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework
    • 9.6.1.3. Target disease prevalence
    • 9.6.1.4. Competitive scenario
    • 9.6.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. China
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Target disease prevalence
    • 9.6.2.4. Competitive scenario
    • 9.6.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. India
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Target disease prevalence
    • 9.6.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. Australia
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework
    • 9.6.4.3. Target disease prevalence
    • 9.6.4.4. Competitive scenario
    • 9.6.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. South Korea
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework
    • 9.6.5.3. Target disease prevalence
    • 9.6.5.4. Competitive scenario
    • 9.6.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Thailand
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Target disease prevalence
    • 9.6.6.3. Regulatory framework
    • 9.6.6.4. Competitive scenario
    • 9.6.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Latin America
  • 9.7.1. Brazil
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework
    • 9.7.1.3. Target disease prevalence
    • 9.7.1.4. Competitive scenario
    • 9.7.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. Argentina
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Target disease prevalence
    • 9.7.2.4. Competitive scenario
    • 9.7.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. MEA
  • 9.8.1. South Africa
    • 9.8.1.1. Key country dynamics
    • 9.8.1.2. Regulatory framework
    • 9.8.1.3. Competitive scenario
    • 9.8.1.4. Target disease prevalence
    • 9.8.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.2. Saudi Arabia
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework
    • 9.8.2.3. Target disease prevalence
    • 9.8.2.4. Competitive scenario
    • 9.8.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.3. UAE
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework
    • 9.8.3.3. Target disease prevalence
    • 9.8.3.4. Competitive scenario
    • 9.8.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.4. Kuwait
    • 9.8.4.1. Key country dynamics
    • 9.8.4.2. Regulatory framework
    • 9.8.4.3. Target disease prevalence
    • 9.8.4.4. Competitive scenario
    • 9.8.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. Merck KGaA
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Takara Bio Inc.
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Revvity, Inc.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Danaher Corporation
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. GenScript
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. New England Biolabs
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Charles River Laboratories
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. Eurofins Scientific
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Lonza
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Thermo Fisher Scientific, Inc.
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives